Dropoetin 2000IU

CLASSIFICATION Glycoprotein Cytokine
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Drogsan
WAREHOUSE International Warehouse 2
SUBSTANCE Erythropoietin ,

Dropoetin is approved for treating anemia linked to chronic renal failure in both pediatric and adult patients undergoing hemodialysis and peritoneal dialysis.

Dropoetin is also indicated for the management of severe renal-origin anemia with clinical symptoms in adult patients who have renal insufficiency but are not yet receiving dialysis.

Additionally, Dropoetin is prescribed to treat anemia and to reduce the need for transfusions in adult cancer patients (excluding those with myeloid malignancies) undergoing chemotherapy.

Dropoetin is indicated for the anemia treatment in adult patients infected with HIV, who are on zidovudine, and exhibit endogenous Dropoetin levels of ≤500 mU/ml.

In adults, Dropoetin may be utilized to support autologous blood collection in a predeposit program and to lower the chances of allogeneic blood transfusions in patients with moderate anemia (hematocrits of 33-39%, hemoglobin of 10-13 g/dL, (6.2-8.1 mmol/l), without iron deficiency), who are scheduled for major elective surgeries that are expected to require more blood than can be acquired through autologous techniques alone. This treatment should only be administered if blood-saving methods are inadequate or unavailable when a significant blood volume (4 or more units for females or 5 or more units for males) is anticipated for the procedure.

Dropoetin is indicated to enhance erythropoiesis during the perisurgical period to decrease the need for allogeneic blood transfusions and to address postoperative anemia in adult patients with moderate anemia (e.g., Hb 10-13 g/dL) who lack access to an autologous blood donation program and are expected to experience moderate blood loss (900 to 1800 ml) during major elective orthopedic surgery.

Dropoetin is also indicated for the treatment of anemia in patients with Low or Intermediate 1-risk Myelodysplastic Syndrome (MDS), specifically for those with hemoglobin levels below 10 g/dL.

Use Dropoetin exactly as prescribed by your physician. Refer to the medication label for specific dosing instructions.

Dropoetin includes a Medication Guide for patients. It is essential to read this guide carefully and review it again each time you refill your prescription.

Typically, Dropoetin is administered as an injection by a healthcare provider in an office, hospital, or clinic setting. If you will be using Dropoetin at home, a healthcare professional will instruct you on proper usage. Ensure that you fully understand how to administer Dropoetin and adhere to the guidance provided during your training. Contact your provider if you have any questions.

When preparing a dose, follow the method shown to you to avoid contaminating the vial, syringe, or medication. Avoid touching the rubber stopper of the vial or the syringe needle with your fingers.

Before administration, always confirm that you have the correct dose drawn up.

Do not shake Dropoetin, and do not use it if it has been shaken or frozen.

Do not dilute Dropoetin or combine it with other solutions unless instructed by your doctor.

For single-dose vials, dispose of any remaining medication after administering your dose. If you have questions about single-dose vials, consult your healthcare provider.

Avoid using Dropoetin if it appears cloudy, discolored, contains particles, or if the vial is cracked or damaged.

It is important to keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles or syringes, and ask your healthcare provider about proper disposal methods after use. Follow all local regulations for disposal.

Continue using Dropoetin, even if you feel well, and do not skip any doses. If you miss a dose, contact your doctor immediately.

Feel free to reach out to your healthcare provider for any questions you may have regarding the use of Dropoetin.

Serious adverse reactions are further discussed in other sections of the label, including: